3:28 PM
Aug 09, 2018
 |  BC Extra  |  Company News

Management tracks: Grail, Celyad, Hua

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Hal Barron and Hans Bishop to its board. Barron is CSO and president of R&D at GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), and Bishop was president and CEO at Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired.

Cell therapy company Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) said CFO Patrick Jeanmart will step down, effective Sept. 3. He will be succeeded by Filippo Petti, who is VP of healthcare investment banking at Wells Fargo Securities LLC.

Diabetes company Hua Medicine Ltd. (Shanghai, China) hired Wenjie Xu as VP, head of commercial strategy and marketing. She was the executive director of the cardiovascular, renal and metabolic business unit for China at AstraZeneca plc (LSE:AZN; NYSE:AZN).

Gene therapy company RegenxBio Inc. (NASDAQ:RGNX) hired Ram Palanki as SVP of commercial strategy and operations. He was SVP of commercial for the Americas at Santen Pharmaceutical Co. Ltd. (Tokyo:4536).

Cancer company Sesen Bio Inc. (NASDAQ:SESN) said CEO Stephen Hurly has left the company. He is succeeded by Thomas Cannell, who was COO and president of global commercial products at Orexigen Therapeutics Inc. (La Jolla, Calif.).

Cardiovascular, metabolic and pulmonary company Vivus Inc. (NASDAQ:VVUS) hired Ken Suh as president. He was president and CEO at Willow Biopharma Inc. (Markham, Ontario).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD